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BACKGROUND Transcatheter Aortic Valve Replacement (TAVR) is
frequently used to treat patients with symptomatic, severe aortic
stenosis in whom surgery is considered to be high-risk or contra-
indicated. Post-procedural para-valvular leak (PVL) remains a signif-
icant issue with a complex etiology. Our objective was to investigate
anatomic and procedural predictors of post-TAVR PVL in patients
undergoing implantation of the self-expandable Corevalve trans-
catheter heart valve (THV).
METHODS 82 patients undergoing TAVR with Corevalve THV who
underwent pre-procedural multi-detector row computed tomography
(MDCT) and intra-procedural transesophageal echocardiography
(TEE) were included. PVL severity was graded using modiﬁed VARC-2
criteria. Annulus dimensions, annulus angulation from the axial
plane, and calcium volume scores1 were measured by MDCT. Pre-
implant peak transaortic velocity, aortic valve effective oriﬁce area
(EOA), left-ventricular stroke volume (LV SV), left-ventricular ejection
fraction (LVEF), and post-implant THV dimensions, implant depth,
and PVL were assessed by TEE. An independent t-test was used to
compare groups.
RESULTS Mean age was 83.0 years and 54% of patients were female.
39 patients (49%) underwent balloon post-dilatation. Age and gender
did not signiﬁcantly differ between patients with > mild and  mild
PVL. Out of the 82 patients studied, 57 had < mild, 14 had mild,
4 had mild-moderate, and 7 had moderate PVL at the end of the
case. No patient had > moderate PVL. Calcium volume score,
annulus angle, baseline transaortic peak velocity, and device size
were signiﬁcantly higher in the > mild PVL group (Table 1). MDCT-
derived % perimeter oversizing, LVEF, and a novel variable of THV
inﬂow expansion (3-dimensional TEE-derived THV inﬂow area/
native annulus area) were signiﬁcantly lower in the > mild PVL
group. Native annulus eccentricity, LV SV, baseline aortic valve EOA,
and echo-derived implant depth were not signiﬁcantly different
between the 2 groups.
Table 1. Variables dichotomized by PVL severityPVL £ mild (n[71) PVL > mild (n[11) p-valuePre-implant variablesAnnulus angle* () 44  11 50  9 0.005
Calcium Volume (mm3) 921  608 1588  563 0.001
Annulus eccentricity 1.3  0.1 1.3  0.1 0.94
Peak transaortic
velocity (m/s)3.6 4.1 0.006EOA (cm2) 0.65  0.18 0.63  0.18 0.75
LV Stroke Volume (ml) 57  18 59  16 0.64
LVEF (%) 54 16 40  21 0.01
Post-implant
variables% Oversizing 18  0.004 13  0.004 0.02
Inﬂow expansion 0.95  0.03 0.69  0.05 0.007
Implant depth, mm 5.50 3.9 6.5  14.8 0.42
THV size, mm 27.5  2.4 29.5  1.5 0.01CONCLUSIONS Among patients undergoing TAVR with a self-
expanding Corevalve THV, PVL severity was related to higher annulus
angle, calcium volume, baseline peak transaortic velocity, THV size,-
lower LVEF, %oversizing, and a novel variable of inﬂow expansion.
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BACKGROUND Transfemoral/Trancutaneous aortic valve implanta-
tion (TAVI) is an alternative to surgical aortic valve replacement
(SAVR) in high risk patients with severe symptomatic aortic stenosis
with good hemodynamic and clinical results. But higher rates of sig-
niﬁcant conduction disturbances with the need for post-interven-
tional pacemaker implantation (PMI) have been reported. Therefore,
the aim of analysis was to determine the frequency of conduction
disturbances and the need for PMI after TAVI and the impact on
procedural and mid-term outcome.
METHODS Patient receiving TAVI at our center between 2006 and
2014 have been enrolled in a prospective single center registry. The
occurrence of conduction abnormalities and the need for PMI has
been recorded in 1700 consecutive patients treated predominately
with the transfemoral approach under local anesthesia. The database
was analyzed with regards to signiﬁcant conduction disturbances, the
need for PMI and the impact on survival.
RESULTS Patients with a mean age of 806 years, a mean STS Score
of 8.56.2% and a logEuroSCORE of 19.813.6% were treated pre-
dominately with the self-expandable Medtronic Core Valve System
(MCV, 64%). The balloon-expandable Edwards SAPIEN valves, other
devices and valve-in-valve procedures have been performed less
frequently (29%, 7%, 4%). The overall pacemaker rate was 28.1% at 30-
days and signiﬁcantly higher in patients treated with the MCV (33.1%)
and other valve types (24.3%) as compared with patients treated with
the Edwards SAPIEN (17.9%; p<0.036). The predominant conduction
disturbances were high grade AV-Block or signiﬁcant bradycardia in
84% of cases. The length of hospital stay and mortality after 30-days
did not differ signiﬁcantly (147 vs. 138 days, p>0.05; 7.0% vs. 7.3%,
p>0.05), whereas patients with a pre-existing PM could be discharged
earlier (103days, p<0.05). The one-year mortality of patients with
PMI after TAVI was not signiﬁcantly different either (20.8% vs. 23.3%,
p>0.05).
CONCLUSIONS These real-life registry data proof that signiﬁcant
conduction disturbances with the necessity of pacemaker implanta-
tion occur frequently. The need of PMI alone does not affect mortality
signiﬁcantly. But further analysis is necessary to evaluate possible
side effects of PMI after TAVI.
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